American Society of Clinical Oncology (ASCO)

Specific types of somatic mutations predicted improved relapse-free survival in patients with acute myeloid leukemia (AML) achieving complete remission.

Results from a large database analysis revealed that a number of risk factors may independently contribute to overall survival in acute myeloid leukemia (AML).

Although idarubicin and cytarabine in combination with clofarabine or fludarabine have similar response profiles in patients with newly diagnosed acute myeloid leukemia (AML), differences in survival were seen between the 2 groups in younger patients.

Variability in surface antigen expression patterns correlated to different outcomes in patients with normal karyotype acute myeloid leukemia (AML).

Timed sequential administration of busulfan may represent a more efficacious approach to the treatment of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Allogeneic stem-cell transplant was found to improve patient outcomes, regardless of age and induction regimen.

Differentiation syndrome, a side effect of enasidenib therapy, can often be managed with pharmacologic interventions and, if necessary, dose interruption.

Although two-thirds of patients with newly diagnosed acute myeloid leukemia (AML) are tested for recurrent mutations, most do not receive the complete panel of guideline-recommended tests.

The majority of newly diagnosed patients with acute myeloid leukemia (AML) were found to be minimal residual disease (MRD)-negative after induction with a crenolanib-containing regimen.